I am engaged in the development of diagnostic methods and the evaluation of the clinical relevance for vasoinhibin, a vasoactive peptide hormone, which is produced by proteolytic cleavage of the pituitary hormone prolactin. The physiological system underlying the regulation and effects of vasoinhibin was first described by us as an endocrine axis in 2015, and named the prolactin/vasoinhibin axis. Clinical relevance, including drug intervention studies intervening in the prolactin/vasoinhibin axis, is demonstrated in diabetic retinopathy and diabetic macular edema, peripartum cardiomyopathy (heart failure that can occur in pregnant women), as well as in pregnancy hypertension (pre-eclampsia). The role of the prolactin/vasoinhibin axis in tumor diseases is currently predominantly investigated at the experimental stage and has not yet been translated to patient studies.
We collaborate with the team of Professor Carmen Clapp Ph.D. of the Institute of Neurobiology of the National University of Mexico. In Nuremberg, I lead a working group consisting mainly of students of the Technical University Nuremberg Georg Simon Ohm from the Department of Applied Chemistry. Also, we are investigating the role of the prolactin/vasoinhibin axis in the development of joint diseases (osteoarthritis) together with the team of the Department of Anatomy of the Paracelsus Medical University Nuremberg under the direction of Professor Gundula Schulze-Tanzil. Our work is supported by the Paracelsus Medical University Nuremberg and the B. Braun Foundation.
I studied medicine in Göttingen and graduated in 2007. I wrote a dissertation on vasoactive peptide hormones and their involvement in complications of diabetes mellitus under Professor Michael Hüfner, then Head of Endocrinology at the University Hospital in Göttingen, and received my doctorate in 2010. At the University Hospitals of Göttingen and Greifswald, I worked in internal medicine in the fields of gastroenterology, endocrinology and rheumatology, including an endocrinology and diabetes outpatient clinic. I switched to the Institute of Neurobiology of the National University of Mexico (Universidad Nacional Autónoma de México, UNAM), where I worked for two years as a Postdoctoral Fellow in the laboratory of Professor Carmen Clapp Ph.D. Here, I continued my specialization in vasoactive peptide hormones and their clinical relevance. Since 2014, I have been a physician at the University Institute for Clinical Chemistry, Laboratory Medicine and Transfusion Medicine of the General Hospital Nuremberg and the Paracelsus Medical University under the direction of Professor Thomas Bertsch.
In this publication, the vasoinhibin nomenclature is explained and a compact overview of publications is shown which have been pathbreaking for the development of the field within the past 40 years:
This publication is an overview of the advancements that have led to the development of clinical trials investigating drug intervention to suppress or stimulate the generation of vasoinhibin in patients:
In the following publication, the physiological principles underlying the regulation and effects of vasoinhibin are described as an endocrine axis, the prolactin/vasoinhibin axis: